Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Other Gross PP&E Adjustments (2023 - 2025)

Indivior Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 3 years, most recently at $219.0 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $219.0 million for Q4 2025, up 52.08% from a year ago — trailing twelve months through Dec 2025 was $219.0 million (up 52.08% YoY), and the annual figure for FY2025 was $219.0 million, up 52.08%.
  • Other Gross PP&E Adjustments for Q4 2025 was $219.0 million at Indivior Pharmaceuticals, up from $200.0 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for INDV hit a ceiling of $219.0 million in Q4 2025 and a floor of $119.0 million in Q4 2023.
  • Median Other Gross PP&E Adjustments over the past 3 years was $167.5 million (2025), compared with a mean of $169.5 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: rose 21.01% in 2024 and later soared 52.08% in 2025.
  • Indivior Pharmaceuticals' Other Gross PP&E Adjustments stood at $119.0 million in 2023, then increased by 21.01% to $144.0 million in 2024, then soared by 52.08% to $219.0 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $219.0 million (Q4 2025), $200.0 million (Q3 2025), and $175.0 million (Q2 2025) per Business Quant data.